- Home
- AGEN vs TBI Comparison
AGEN vs TBI Comparison
Compare AGEN & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- TBI
- Stock Information
- Founded
- AGEN 1994
- TBI 1985
- Country
- AGEN United States
- TBI United States
- Employees
- AGEN N/A
- TBI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- TBI Professional Services
- Sector
- AGEN Health Care
- TBI Consumer Discretionary
- Exchange
- AGEN Nasdaq
- TBI Nasdaq
- Market Cap
- AGEN 142.8M
- TBI 169.2M
- IPO Year
- AGEN 2000
- TBI 1996
- Fundamental
- Price
- AGEN $4.55
- TBI $6.47
- Analyst Decision
- AGEN Buy
- TBI Buy
- Analyst Count
- AGEN 2
- TBI 1
- Target Price
- AGEN $14.50
- TBI $8.00
- AVG Volume (30 Days)
- AGEN 395.5K
- TBI 107.5K
- Earning Date
- AGEN 11-11-2025
- TBI 11-03-2025
- Dividend Yield
- AGEN N/A
- TBI N/A
- EPS Growth
- AGEN N/A
- TBI N/A
- EPS
- AGEN N/A
- TBI N/A
- Revenue
- AGEN $101,706,000.00
- TBI $1,534,863,000.00
- Revenue This Year
- AGEN $60.49
- TBI $2.21
- Revenue Next Year
- AGEN N/A
- TBI $6.18
- P/E Ratio
- AGEN N/A
- TBI N/A
- Revenue Growth
- AGEN N/A
- TBI N/A
- 52 Week Low
- AGEN $1.38
- TBI $3.45
- 52 Week High
- AGEN $7.34
- TBI $9.05
- Technical
- Relative Strength Index (RSI)
- AGEN 48.05
- TBI 59.05
- Support Level
- AGEN $4.36
- TBI $5.41
- Resistance Level
- AGEN $5.20
- TBI $6.66
- Average True Range (ATR)
- AGEN 0.27
- TBI 0.29
- MACD
- AGEN 0.04
- TBI 0.09
- Stochastic Oscillator
- AGEN 40.91
- TBI 84.40
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.